Navigation Links
3SBio Inc. To Report 2010 First Quarter Unaudited Financial Results on May 16, 2010
Date:5/11/2010

SHENYANG, China, May 11 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial results for the first quarter ended March 31, 2010 on May 16, 2010 at 8:00pm (Eastern).

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on May 17, 2010 to discuss its 2010 first quarter financial results and recent business activity.

    The conference call may be accessed using the dial-in numbers below:

    Conference ID: 74760426

    Local dial-in:
    China - landline 800 819 0121
    China - mobile 400 620 8038
    Hong Kong - 852 2475 0994

    International toll-free dial-in:
    Hong Kong 800 930 346
    United Kingdom 080 8234 6646
    United States 1 866 519 4004
    International toll dial-in: 65 6723 9381

A telephone replay will be available two hours after the call until May 24, 2010 at:

    International dial-in: +61-2-8235-5000
    United States dial-in: 1-866-214-5335
    Replay- Conference ID: 74760426

Webcast

A live webcast of the conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/3sbio2010Q1 . A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3SBio.com

    Investor Contacts

     Bo Tan
     Chief Financial Officer
     3SBio Inc.
     Tel:   +86-24-2581-1820
     Email: ir@3SBio.com

     Tom Folinsbee
     Director of Investor Relations
     3SBio Inc.
     Tel:   +852-8191-6991
     Email: ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Announces Changes to its Board of Directors
2. 3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial
3. 3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
4. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
5. 3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia
6. 3SBio Inc. to Report 2009 Fourth Quarter and Full Year Results on February 11, 2010
7. 3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
8. 3SBio Inc. Announces Unaudited Third Quarter 2009 Results
9. 3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
10. 3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
11. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Conference 2016, to be held February 8-9, 2016, at ... 2016 Disruptive Growth & Healthcare Conference, taking place in ... 2016. James Sapirstein , Chief Executive Officer ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
Breaking Biology News(10 mins):